Table 2.
Ancillary study |
Case 1
|
Case 2
|
Case 3
|
||||||
---|---|---|---|---|---|---|---|---|---|
Primary | First recurrence | Second recurrence |
Primary
|
First recurrence |
Second recurrence |
Primary
|
|||
PTC comp. | MASC comp. | PTC comp. | MASC comp. | ||||||
S-100 | Pos (rare cells) | ND | Pos (rare cells) | Neg | Pos (rare cells) | Pos (focally) | Pos (focally) | Neg | Pos |
Mammaglobin | Pos | ND | Pos | Neg | Pos | Pos | pos | Neg | Pos |
GCDFP-15 | Pos (focally) | ND | Pos (focally) | Neg | Neg | ND | Neg | Neg | Pos (focally) |
p63 | Pos (focally) | ND | ND | Neg | Pos (focally) | ND | ND | Neg | Pos |
PAX8 | Pos (weak) | ND | Pos (rare cells) | Pos | Pos (weak) | Pos (weak) | Pos | Pos | Pos (weak) |
TTF-1 | Neg | Neg | Neg | Pos | Neg | Neg | Neg | Pos | Neg |
Thyroglobulin | Neg | Neg | Neg | Pos | Neg | Neg | Neg | Pos | Neg |
CK7 | Pos | Pos | Pos | Pos | Pos | Pos | Pos | Pos | Pos |
CK19 | Pos | ND | Pos | Pos (weak) | Pos | Pos | Pos | Pos (weak/very focally) | Pos |
Vimentin | Pos | ND | ND | Pos (very focally) | Neg | ND | ND | Pos | Pos |
Mucicarmine | Pos | ND | Pos | Neg | Pos | ND | Pos | Neg | Neg |
Calponin | ND | ND | Neg | ND | ND | ND | Neg | Neg | Neg |
Her-2/Neu | ND | ND | Neg | ND | ND | ND | Neg | Neg | Neg |
AR | ND | ND | Neg | ND | ND | ND | Neg | Neg | Neg |
Ki-67 | 1–2% (3/10) | ND | 7% | <1% | <1% | ND | 2% | <1% | 5% |
ETV6 FISH | Pos | ND | Pos | Pos | Pos | ND | Pos | Pos | Pos |
MSK-IMPACT | ND | ND | ETV6–NTRK3 | ETV6–NTRK3 | ETV6–NTRK3 | ETV6–NTRK3 | ND | ||
ETV6 P214L (c.641C>T) | APC R640W (c.1918C>T) | ||||||||
KDM5C G496R (c.1486G>C) | HNF1A E619K (c.1855G>A) | ||||||||
PPP2R1A R182W (c.544C>T) | SYK R22Q (c.65G>A) |
ND, not done; PTC, papillary thyroid carcinoma; MASC, mammary analog secretory carcinoma; FISH, fluorescence in situ hybridization.